ClinicalTrials.gg
RecruitingNCT07432633Updated Oct 28, 2026

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

A Phase 1/2 interventional study of [18F]FPyQCP in Colorectal Cancer, Epithelial Ovarian Cancer and Gastric Cancer, sponsored by Blue Earth Diagnostics. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 28, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,341 studies in Colorectal Neoplasms with a site in United States — 417 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
918th of 1,933
71 · median 64
Started
2026
with 118 others
Phase 1/2
266 of 2,341
68 open now
Primary completion
2028-01
later than 384 of 627 live
Registered
2,258th of 2,341
by date

Among the 2,341 studies in Colorectal Neoplasms with a site in United States, this one is the 918th largest by planned enrollment of the 1,933 interventional ones that give a count, is one of 119 that started in 2026, is one of 266 in phase 1/2, reaches primary completion later than 384 of the 627 other live ones, and was the 2,258th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

417 of the 2,341 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 417 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,341 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

03

Conditions studied

  • Colorectal Cancer
  • Epithelial Ovarian Cancer
  • Gastric Cancer
  • Invasive Lobular Breast Carcinoma
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Positron emission tomography
  • Fibroblast activation protein
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants provide and confirm that they are able and willing to comply with all protocol requirements.
  2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent.
  3. performance status ≤ 2.
  4. Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology).
  5. Women of (WOCBP) should have a negative serum test at screening (Visit 1) and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to [18F]FPyQCP administration.
  6. WOCBP, and men who are sexually active with WOCBP, must agree to use a highly effective method(s) of for the duration of the study
  7. Cohort A specific: Participants with stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease [5 or fewer known ) as assessed by conventional imaging within 8 weeks of [18F]FPyQCP administration.
  8. Cohort B specific: Conventional imaging performed within 8 weeks of screening and no later than 24 hours before [18F]FPyQCP administration and available for upload to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis.
  9. Either:

    1. Treatment-naïve with at least stage IIB disease. Available sample or scheduled biopsy or surgical resection no later than Day 42.
    2. Following therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day 42. [18F]FPyQCP PET/CT imaging should be performed as close to scheduled procedure as clinically feasible.
    3. Suspected recurrence after definitive therapy

Exclusion criteria

Exclusion Criteria:

  1. Participants administered any radioisotope within 5 physical half-lives prior to [18F]FPyQCP administration.
  2. Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to [18F]FPyQCP administration.
  3. Participants who have recently received any other contrast agent (\< 24 hours for intravenous agents and \< 5 days for oral agents) before the day of [18F]FPyQCP administration.
  4. Participants with a history of severe claustrophobia or panic attacks when in confined spaces.
  5. Known to [18F]FPyQCP or any of its constituents.
  6. Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion.
  7. Known diagnosis of an or inflammatory disorder that is expected to confound image interpretation per investigator judgment, excluding disorders directly related to the index cancer (e.g. tumor-associated pancreatitis or biliary stasis for PDAC).
  8. Medical history of abdomino-pelvic or breast irradiation in the last 3 months.
  9. Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgment.
  10. Significant renal or hepatic impairment.
  11. Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the [18F]FPyQCP administration.
  12. Cohort A Specific Exclusion Criteria: 12. No prior history of any other cancer, unless treated with curative-intent and disease-free for at least 5 years before Visit 1 (at least 1 year before Visit 1 for basal cell carcinoma, localized squamous cell carcinoma of the skin and in situ carcinoma of cervix).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    [18F]FPyQCP PET/CT

    Each participant will receive \[18F\]FPyQCP followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2)

    Drug: [18F]FPyQCP

Interventions

  • Drug[18F]FPyQCP

    positron emission tomography (PET)/computed tomography (CT) imaging

06

What researchers measure

Primary outcomes

  1. Assess radiation dosimetry of [18F]FPyQCP (Cohort A)

    Whole body effective dose of a single dose of \[18F\]FPyQCP

    Time frame: Up to 360 minutes post injection

  2. Assess the diagnostic performance of [18F]FPyQCP in the peritoneum (Cohort B)

    Sensitivity and specificity of \[18F\]FPyQCP PET/CT compared to composite standard of truth

    Time frame: Until completion of follow-up procedures, up to 42 days post injection

Secondary outcomes

  1. Incidence and severity of adverse events using CTCAE version 5.0 (Both Cohorts)

    Purpose is to evaluate the safety and tolerability of \[18F\]FPyQCP

    Time frame: From screening until safety follow-up (48 hours post injection)

  2. Further assess the diagnostic performance of [18F]FPyQCP (Cohort B).

    Participant and region level diagnostic performance (where calculable: sensitivity, specificity, positive predictive value, and negative predictive value) with \[18F\]FPyQCP PET/CT compared to composite SOT and participant and region level detection rates.

    Time frame: Until completion of follow-up procedures, up to 42 days post injection

07

Study locations

1 of 2 sites recruiting
  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
    New York, New York 10032, United States
    Not yet recruiting
    • Mikhail Doubrovin, MD · Contact
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • Steven Rowe, MD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 23 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 25, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital · New York, United States
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    1 site added
    Show site
    • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07432633
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Feb 19, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Jamie MacKay, MD, PhD
Contact
jamie.mackay@blueearthdx.com
+447350456887
Evgenia Perkins
Contact
evgenia.perkins@blueearthdx.com
+19139576499
Steven Rowe, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion